← Back to Search

Cell Therapy

Stem Cell Transplant for Leukemia and Lymphoma

Phase 2
Recruiting
Led By Jordan Milner, MD
Research Sponsored by University of Florida
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will test a new method of stem cell transplantation for patients with certain types of leukemia and lymphoma. The study will look at how safe and effective it is to remove certain types of cells from

Who is the study for?
This trial is for patients with certain blood cancers like ALL, AML, CML, lymphoma and high-risk MDS. Participants should be in specific stages of their disease such as first or second remission or have a limited amount of cancer cells in the bone marrow. It's not open to those who don't meet these specific conditions.
What is being tested?
The study tests a stem cell transplant technique using the Miltenyi CliniMACS Prodigy system to remove certain immune cells (⍺/β CD3+ T-cells and CD19+ B-cells) from donor cells before transplantation into patients with various malignant diseases.
What are the potential side effects?
Potential side effects may include complications related to stem cell transplants such as infections due to weakened immunity, graft-versus-host disease where donor cells attack the body, and reactions during infusion.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Acute graft versus host disease (aGVHD) incidence
Secondary study objectives
Adenovirus viremia incidence
Cytomegalovirus (CMV) viremia incidence
Epstein-Barr virus (EBV) viremia incidence
+4 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Allogeneic stem cell transplant with ⍺/β CD3+ T-cell and CD19+ B-cell depleted graftExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Florida Department of HealthOTHER_GOV
29 Previous Clinical Trials
13,009 Total Patients Enrolled
Ocala Royal Dames for Cancer ResearchUNKNOWN
University of FloridaLead Sponsor
1,397 Previous Clinical Trials
767,040 Total Patients Enrolled
~13 spots leftby May 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top